by [email protected] | Aug 16, 2022 | Cardiovascular, Publication
Abstract Background Oral anticoagulants (OACs) mitigate stroke risk in patients with atrial fibrillation (AF). The study aim was to analyze prevalence and predictors of OAC underutilization. Methods Newly diagnosed AF patients with a CHA2DS2-VASc score ≥ 2 were...
by [email protected] | Jul 23, 2022 | Cardiovascular, Publication, Pulmonary
Abstract BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare, progressive, and fatal disease associated with considerable overall clinical and economic burden. Although the direct health care costs of PAH have been well described, there are few data...
by [email protected] | Jun 2, 2022 | Cardiovascular, Publication
Abstract Real-world studies have evaluated the use of anticoagulants in obese patients with nonvalvular atrial fibrillation (NVAF), but they have been limited by sample size or the use of diagnosis codes on claims to define obesity. This retrospective study used body...
by [email protected] | Apr 28, 2022 | Cardiovascular, Publication
Abstract Background: Oral anticoagulants (OACs) mitigate the risk of stroke in atrial fibrillation (AF) patients. Objective: Elderly AF patients who were treated with OACs (apixaban, dabigatran, edoxaban, rivaroxaban, or warfarin) were compared against AF patients who...
by [email protected] | Apr 28, 2022 | Cardiovascular, nephrology, Publication
Abstract There has been limited evidence reported about the outcomes of oral anticoagulants among patients with venous thromboembolism (VTE) and chronic kidney disease (CKD), especially those with stage V/end-stage renal disease (ESRD). This retrospective cohort...
by [email protected] | Jan 24, 2022 | Cardiovascular, Publication
Abstract Importance Many patients with nonvalvular atrial fibrillation (NVAF) are at a high risk of gastrointestinal (GI) bleeding due to conditions including older age; stage III to V chronic kidney disease (CKD); HAS-BLED (hypertension, kidney or liver disease,...
